Premium
P2‐377: A phase 2, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL‐108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment
Author(s) -
Schmechel Donald E.,
Gerard Gary,
Vatakis Nick G.,
Harper Linda,
Ross Joel S.,
Bari Mohammed,
Walling David,
Stedman Mary,
Winston Jaron L.,
Morimoto Bruce,
Keith Julian R.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.1455
Subject(s) - tolerability , medicine , placebo , neuroprotection , psychology , adverse effect , pathology , alternative medicine